Full Press Release Details
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
CVM Positive Sentiment
CEL-SCI Reports Fiscal Third Quarter 2026 Results
Key Takeaway: CEL-SCI has announced its financial results for the third quarter of fiscal 2026, which ended on June 30. The report includes significant updates on corporate and clinical developments related to Multikine. This reflects the company's ongoing efforts in advancing its product pipeline.
Market Sentiment Analysis
POSITIVE FACTORS
- CEL-SCI reported financial results for the third quarter.
- Key corporate and clinical developments were highlighted.
- The report indicates ongoing progress with Multikine.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~4 mo
High dilution risk
Lead asset
LI
Phase 3 · Squamous Cell Carcinoma of the Oral Cavity
Frequently Asked Questions
What financial results did CEL-SCI report?
CEL-SCI reported its financial results for the third quarter ended June 30, 2026.
What is Multikine?
Multikine is a product developed by CEL-SCI, with ongoing clinical and corporate developments.
When did CEL-SCI's fiscal third quarter end?
The fiscal third quarter for CEL-SCI ended on June 30, 2026.
What key updates were included in the report?
The report highlighted key corporate and clinical developments related to Multikine.